Experts Urge More Use Of Evista And Other Drugs To Prevent Breast Cancer
Movement toward a paradigm shift in breast cancer from reactive treatment to prevention could gain support from the long-term results of the Study of Tamoxifen and Raloxifene (STAR) trial
You may also be interested in...
Lilly has decided not to submit the NDA for its osteoporosis drug arzoxifene after Phase III data showed the drug fell short on key secondary outcome measures, the firm announced Aug. 18
Merged Pfizer/Wyeth will likely have to choose between Viviant and Fablyn.
The long-term data from Pfizer's PEARL study are the firm's best bet for eking out a competitive distinction for its osteoporosis drug Fablyn against Lilly's Evista. FDA, however, seems less inclined to put those findings in labeling, particularly the breast cancer data